Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024. 

"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."

Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month. 

The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses. 

Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent. 

Share:
More In Business
The Day Ahead: Earnings, Key Economic Data, National Wine Day
Cheddar News checks in to see what to look out for on The Day Ahead as earnings continue with reports from Gap, Best Buy, Costco Wholesale and Ulta Beauty while key economic data is also due to be released. It's also National Wine Day on Thursday.
Iconic Movie Props Up for Auction
Over 1,400 props from classic movies like Star Wars, Shawshank Redemption and Gladiator will be up for auction next month in what experts say will be one of the largest memorabilia auctions in the world.
EU, Google to Develop Voluntary A.I. Pact
The European Union and Google are looking to develop a voluntary artificial intelligence pact with European and non-European companies ahead of rules to govern the technology.
FTC Investigating Baby Formula Makers
The Federal Trade Commission is investigating whether baby formula makers colluded in bidding on state contracts, according to documents posted on the agency's website.
Load More